Factors associated with bleeding complications in patients with coronavirus disease 2019 admitted to intensive care units: A multicenter retrospective cohort study.
Bleeding complication
COVID-19
Diabetes
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
07
07
2023
received:
30
03
2023
accepted:
23
07
2023
medline:
23
10
2023
pubmed:
15
8
2023
entrez:
15
8
2023
Statut:
ppublish
Résumé
Diabetes is a major risk factor for coronavirus disease 2019 (COVID-19) severity. We aimed to retrospectively investigate the rates of patients with no diabetes, untreated diabetes, treated diabetes, COVID-19-related diabetes and the factors associated with bleeding complications in a cohort of patients with severe COVID-19. This was a multicenter, retrospective, observational study. Participants were COVID-19 patients enrolled in the Cross-sectional ICU Information Search System (CRISIS) from February 2020 to March 2022. Patients were classified into four groups according to diabetes status and treatment status. Hemorrhagic complications were defined as bleeding requiring transfusion of four or more red blood cell units, a drop of hemoglobin of ≥2 g in 24 h and retroperitoneal, airway or intracranial bleeding. Logistic regression analysis was carried out to examine factors associated with bleeding complications. A total of 1,076 patients were included in the analysis. The rates of patients in the no diabetes, untreated diabetes, treated diabetes and COVID-19-related diabetes groups were 17.4, 23.0, 23.9 and 35.7%, respectively. Bleeding complications were observed in 7.5% of all patients. Glycated hemoglobin level and renal failure were significantly correlated with bleeding complications (odds ratio 1.16, 95% confidence interval 1.02-1.33 and 2.77, 95% confidence interval 1.16-6.63, respectively). Patients with diabetes, including those with COVID-19-related diabetes, accounted for approximately 83% of all cases. In patients with severe COVID-19 with high glycated hemoglobin and renal failure, we recommend additional attention to the course of COVID-19, given the risk of bleeding complications.
Identifiants
pubmed: 37581471
doi: 10.1111/jdi.14068
pmc: PMC10583641
doi:
Substances chimiques
Glycated Hemoglobin
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1312-1317Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP22fk0108654
Informations de copyright
© 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Heliyon. 2022 Jan;8(1):e08801
pubmed: 35079646
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Thromb J. 2021 Mar 3;19(1):13
pubmed: 33658062
Br Med J. 1976 Sep 11;2(6036):612-5
pubmed: 786433
Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):264-72
pubmed: 22053073
BMJ. 2022 Apr 6;377:e069590
pubmed: 35387772
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
EClinicalMedicine. 2021 Sep;39:101075
pubmed: 34493997
Rev Mal Respir. 2014 Oct;31(8):779-95
pubmed: 25391514
Hosp Pract (1995). 2021 Dec;49(5):307-324
pubmed: 34807786
Internist (Berl). 2022 Apr;63(4):453-460
pubmed: 35290499
Curr Med (Cham). 2022;1(1):6
pubmed: 35673632
Am J Respir Crit Care Med. 2003 Dec 15;168(12):1449-56
pubmed: 12947028
J Biol Chem. 2001 Nov 9;276(45):42077-83
pubmed: 11546817
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2128-2130.e2
pubmed: 32334082
Eur Arch Otorhinolaryngol. 2022 Jun;279(6):3095-3103
pubmed: 34637016
J Neuroimaging. 2020 Sep;30(5):555-561
pubmed: 32776617
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
Bosn J Basic Med Sci. 2022 Apr 01;22(2):270-279
pubmed: 34812131
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
J Intensive Care Med. 2022 Mar;37(3):304-318
pubmed: 34636697